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Abstract
Background: Zoledronic acid is used to treat bone metastases and has been shown to reduce skeletal-related
events and exert antitumor activity. The present in vitro study investigates the mechanism of action of Zoledronic
Acid on breast cancer cell lines with different hormonal and HER2 patterns. Furthermore, we investigated the
efficacy of repeated versus non-repeated treatments.
Methods: The study was performed on 4 breast cancer cell lines (BRC-230, SkBr3, MCF-7 and MDA-MB-231).
Non-repeated treatment (single exposure of 168 hrs’ duration) with zoledronic acid was compared with repeated
treatment (separate exposures, each of 48 hrs’ duration, for a total of 168 hrs) at different dosages. A dose–response
profile was generated using sulforhodamine B assay. Apoptosis was evaluated by TUNEL assay and biomolecular
characteristics were analyzed by western blot.
Results: Zoledronic acid produced a dose-dependent inhibition of proliferation in all cell lines. Anti-proliferative
activity was enhanced with the repeated treatment, proving to be statistically significant in the triple-negative lines.
In these lines repeated treatment showed a cytocidal effect, with apoptotic cell death caused by caspase 3, 8 and 9
activation and decreased RAS and pMAPK expression. Apoptosis was not observed in estrogen receptor-positive
line: p21 overexpression suggested a slowing down of cell cycle. A decrease in RAS and pMAPK expression was
seen in HER2-overexpressing line after treatment.
Conclusions: The study suggests that zoledronic acid has an antitumor activity in breast cancer cell lines. Its
mechanism of action involves the decrease of RAS and RHO, as in osteoclasts. Repeated treatment enhances
antitumor activity compared to non-repeated treatment. Repeated treatment has a killing effect on triple-negative
lines due to apoptosis activation. Further research is warranted especially in the treatment of triple-negative breast
cancer.
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Background
Breast cancer is the most commonly diagnosed cancer
in women in developed countries and over 50% of
patients have bone involvement at relapse [1-4]. Bone
metastasis is a major epidemiological and clinical prob-
lem in women with breast cancer, causing pain and
other serious complications such as pathologic fracture,
spinal cord compression and hypercalcemia with poor
quality of life and prognosis [5,6].
The skeleton is characterized by a dynamic balance be-
tween osteoclast (induced bone resorption) and osteo-
blast (stimulated bone formation) bone remodeling,
which maintains physiological bone turnover. The diffu-
sion of tumor cells in bone tissue breaks this process
causing the disruption of bone integrity and serious skel-
etal complications [7-9]. Bone metastases from breast
cancer are most often lytic, so that bone homeostasis is
shifted toward bone resorption by osteoclasts.
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Bisphosphonates are potent antiresorptive drugs in
widespread use that are well suited to the treatment of
metabolic bone disease. These drugs bind avidly to hy-
droxyapatite crystals at sites of active bone metabolism,
achieving therapeutic concentrations. Bisphosphonates
are released during bone resorption and are internalized
by osteoclasts, leading to inhibition of bone resorption
itself and induction of osteoclast apoptosis [10].
The use of drug treatments has a positive impact on
the quality of life, inducing both a reduction of skeletal
related events (SRE) and death risk in patients with bone
metastases from breast cancer [11-13]. In particular,
Zoledronic acid (Zol) is a potent third-generation nitro-
gen-containing bisphosphonate, and, in recent years, it
has had widespread clinical use in patients with breast
cancer [14]. Furthermore, many preclinical studies have
demonstrated that Zol has both direct and indirect
tumor activity, reducing proliferation and viability of
tumor cell lines in vitro [15]. The direct action occurs
in a dose and time dependent manner to inhibit prolif-
eration and induce apoptosis in breast cancer cell lines
[16]. The indirect action depends on the modification
of bone microenvironment that is less hospitable for
cancer cells’ growth. Furthermore, Zol is known to in-
hibit tumor cell adhesion and invasion [17,18] and its
potential antiangiogenic activity has recently been dis-
covered [19,20]. In animal models, a reduction in skel-
etal tumor burden and slower progression of bone
lesions was observed after Zol treatment [21,22]. Re-
cent clinical data in the adjuvant setting of breast can-
cer has also shown that Zol also increases disease-free
survival [23,24].
However, one of the most important limitations of Zol
which makes its direct anticancer effect difficult to dem-
onstrate in vivo is its pharmacokinetics profile. After a
4-mg infusion the drug remains in the plasma circula-
tion for 1–2 hours before localization to the bone, with
a plasmatic peak of 1 μM. Studies on rats and dogs have
shown that Zol levels rapidly decrease in plasma and
non calcified tissue, whereas higher levels persist in bone
and slowly diminish, with a half-life of about 240 days.
Such results would seem to indicate that a part of Zol is
reversibly taken up by the skeleton and that the dispos-
ition in blood and non calcified tissue is controlled by
extensive uptake into and slow release from bone. The
anticancer activity of this drug could be improved by in-
creasing the availability of the drug in tissue outside the
bone and by encapsulating it in liposome vehicles to
lengthen its plasma half life. Other strategies could be to
change the treatment schedule to low-dose protracted
administration or to use synergistic combinations of
drugs [25,26].
Several Zol dosing schedules have been proposed for
the treatment of osteoporosis and bone metastases
[27,28]. However, these schedules need to be optimized
to maximize its antitumor effects [29,30]. The metro-
nomic approach has already been studied, and, in par-
ticular, daily or repeated therapies with bisphosphonates
have been reported to inhibit skeletal tumor growth in
mouse models [21]. In cancer patients with bone metas-
tases, repeated intermittent low-dose therapy with Zol
has been shown to induce a decrease in VEGF levels in
cancer patients.
The aim of this study is to compare the cytotoxic
activity of repeated and non-repeated Zol treatment in
4 breast cancer cell lines that differ in their hormone
receptors’ and HER2 status. We also investigated the




The study was performed on four breast cancer cell
lines, MCF-7, SKBr3, MDA-MB-231, obtained from the
American Type Culture Collection (Rockville, MD), and
BRC-230, established in our laboratory [31]. Hormone
receptor and HER2 status are listed in Figure 1. The cell
lines were maintained as a monolayer at 37°C and
subcultured weekly. Culture medium was composed of
45% HAM F12 and 45% DMEM supplemented with 10%
fetal calf serum, 1% insulin and 1% glutamine (Mascia
Brunelli s.p.a., Milan, Italy). Cells were treated with Zol
24 hrs after seeding. Cells in the exponential growth
phase were used for all experiments.
Drugs
Zoledronic acid (ZometaW) (Zol), kindly provided by
Novartis (Milan, Italy), was solubilized and stored at a
concentration of 50 mM in sterile water at −20°C and
diluted in medium before use. Cells were exposed to
12.5, 25 and 50 μM of Zol in chemosensitivity assay, and
to 50 μM of Zol for apoptosis and western blot analysis.
Chemosensitivity assay
Sulforhodamine B (SRB) assay was used according to the
method of Skehan et al. [32]. Briefly, cells were trypsi-
nized, counted and plated at a density of 3,000 cells/well
in 96-well flat-bottomed microtiter plates (200 μl of cell
suspension/well). In the chemosensitivity assay, experi-
ments were run in octuplicate, and each experiment was
repeated three times [33]. The optical density (OD) of
cells was determined at a wavelength of 540 nm by a col-
orimetric plate reader. Growth inhibition and cytocidal
effect of drugs were calculated according to the formula
reported by Monks et al. [34]: [(ODtreated - ODzero)/
(ODcontrol - ODzero)] × 100%, when ODtreated is ≥ODzero.
If ODtreated is above ODzero, treatment has induced a
cytostatic effect, whereas if ODtreated is below ODzero, cell
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killing has occurred. The ODzero depicts the cell number
at the moment of drug addition, the ODcontrol reflects the
cell number in untreated wells and the ODtreated reflects
the cell number in treated wells on the day of the assay.
Single drug exposure
In the chemosensitivity assay, cells were exposed to
repeated (RS) and non-repeated schedules (NRS). In
NRS experiments, cells were exposed for 168 hrs, while
in the RS experiments, cells were exposed every 48 hrs
to the same Zol concentration (Figure 1). All experi-
ments were performed in triplicate and results were
reported as the mean 50% inhibitory concentrations
(IC50) of cell growth.
Treatment of cells for apoptosis evaluation, western blot
and pull-down assay
Cells were plated at a density of 106 cells in a flask
(75 cm2) and were treated 24 hrs after seeding with
50 μM of Zol according to the two schedules described
above. For apoptosis analysis, cells were detached from
the flasks by trypsin at the end of treatment, washed
twice with PBS and stained according to the different
methods specified below. For western-blot analysis,
cells were detached from the flasks and were then lysed
by shaking for 5 minutes in B-PER Mammalian Protein
Extraction Reagent (Pierce, Rockford, IL). For pull-
down analysis, post-treatment cells were stimulated
by EGF 100 ng/ml for 10 minutes at 37°C (Miltenyi,
Bologna Italy ) to evaluate Ras activity, and by Rho
activator 1 (Cytoskeleton, Denver, CO) 1 U/ml for
30 min at 37°C to assess Rho activity. Cells were then
washed once with PBS, lysed by cell lysis buffer
(Cytoskeleton) and detached using a scraper. Protein
concentration was assessed using BCA Protein Assay
kit (Pierce).
Wound scratch
Wound scratch assay was used to determine the migra-
tion of the four cell lines after Zol treatment (after
168 hrs). Cells were grown in flasks and the two treat-
ments were performed. Twenty-four hours before stop-
ping, a uniform cell-free area was created by scratching
a confluent monolayer with a scraper. Wound closure
was observed at the end of the experiments to determine
cell line migration [35].
Western blot
An equal quantity of proteins was denatured and sepa-
rated on Criterion-HCL gel 12.5% Tris (Bio-Rad, Hemel
Hempstead, UK) and electroblotted onto Immobilon-P
Transfer Membrane (Millipore). The membrane was
stained with Ponceau S (Sigma Aldrich, Milan, Italy) to
verify equal amounts of sample loading and then incu-
bated for 2 hrs at room temperature with T-PBS 5% non
fat dry milk (Bio-Rad). The membrane was probed over-
night at 4°C with the specific primary antibody, after
which horseradish peroxidise-conjugated secondary anti-
body diluted 1:5,000 (Santa Cruz Biotechnology Inc,
Santa Cruz, CA) was added. Bound antibodies were
detected by Immun-Star Western C kit (Bio-Rad), using
Chemidoc XRS Molecular Imager (Bio-Rad). The follow-
ing primary antibodies were used: anti-p21 (monoclonal,
1:100) (BioOptica, Milan, Italy), anti-caspase 3 (poly-
clonal, 1:500), anti-caspase 9 (polyclonal, dilution 1:500),
anti-bax (polyclonal, 1:1000), anti-pMAPK (polyclonal,
1:1000) (Cell Signalling Technology, Inc., Beverly, MA),
anti-caspase 8 (monoclonal, 1:500) (Alexis Biochemicals,
San Diego, CA), anti-RAS (polyclonal, 1:1000) (Stress-
gen, Exeter,UK), anti-Bcl-2 (monoclonal, 1:100) (Dako
Corporation, Glostrup, Denmark), anti MCL-1 (mono-
clonal 1:100) (BD Pharmingen, San Jose, CA), anti rap1
(monoclonal 1:1000) (Abcam, Cambridge, UK) and anti-
Figure 1 Treatment scheduling and biological characteristics of cell lines used.
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actin (polyclonal, 1:5000) (Sigma Aldrich), anti p-27
(monoclonal 1:2500) (BD Pharmingen, San Jose) and anti-
MAPK (polyclonal 1:1000) (Cell Signaling Technology).
Ras and Rho activity evaluation
The Ras/Rho Activation Assay Biochem kit (Cytoskel-
eton) was used according to the manufacturer’s instruc-
tions. Briefly, we performed a pull- down analysis of the
RAF-RBD/GTP-Ras complex and GTP-RHO Rhotekin-
RBD [36,37]. The amount of activated Ras was then
determined by quantitative western blot using a Ras and
Rho pan specific antibody. Band density was evaluated
by Quantity one software.
Apoptosis
For TUNEL assay, at the end of treatment cells were
fixed in 1% paraformaldehyde in PBS on ice for 15 min-
utes, suspended in ice cold ethanol (70%) and stored
overnight at −20°C. Cells were then washed twice in PBS
and resuspended in PBS containing 0.1%
Triton X-100 for 5 minutes at 4°C. Thereafter, samples
were incubated in 50 μl of solution containing TdT and
FITC-conjugated dUTP deoxynucleotides 1:1 (Roche
Diagnostics GmbH, Mannheim, Germany) in a humidi-
fied atmosphere for 90 minutes at 37°C in the dark,
washed in PBS, counterstained with propidium iodide
(2.5 μg/ml, MP Biomedicals, Verona, Italy) and RNAse
(10 Kunits/ml, Sigma Aldrich) for 30 minutes at 4°C in
the dark and analyzed by flow cytometry.
Flow cytometric analysis was performed using a FACS-
Canto flow cytometer (Becton Dickinson, San Diego,
CA). Data acquisition and analysis were performed using
FACSDiva software (Becton Dickinson). Samples were
run in triplicate and 10,000 events were collected for
each replica. Data were the average of three experiments,
with errors under 5%.
Cell cycle
After Zol treatment and the different washouts
(168 hrs), cells were fixed in ethanol (70%), stained in a
solution containing propidium iodide (10 mg/ml, MP
Biomedicals, Verona, Italy), RNAse (10 kunits/ml, Sigma
Aldrich) and NP40 (0.01%, Sigma Aldrich) overnight at
4°C in the dark, and analyzed by flow cytometry. Data
were expressed as fractions of cells in the different cell
cycle phases. A pulse-chase experiment was performed
on MDA-MB-231 treated with RS to evaluate S Phase.
MDA-MB-231 was used because it was the most sensi-
tive cell line to Zol. Samples were taken at baseline, after
72 and 168 hrs’ treatment, and after a 48-hr washout.
Bi-parametric BrdU-DNA content determination
BrdU (20 mM, Sigma Aldrich) was added to cell
medium 15 minutes before the start of scheduled
treatment. Cells were incubated using the previously
reported drug concentrations or in control medium. At
the end of each exposure time, cells were fixed in ice-
cold ethanol (70%), stored overnight at −20°C, washed
twice in PBS and incubated in HCl 2N for 25 min at
room temperature. Samples were then washed with 4 ml
of Na2B4O7 (0.1 M, pH8.5, Sigma Aldrich, Milan, Italy),
incubated for 15 min at room temperature in PBS con-
taining 0.5% Tween 20 (Biorad) and BSA 1% (Sigma
Aldrich) and incubated with an anti-BrdU mouse anti-
body (NeoMarkers) (1/50 dilution in 0.5% Tween 20 and
BSA 1%) for 1 hr at room temperature in the dark. Cells
were washed in PBS and incubated with a FITC-
conjugated anti-mouse immunoglobulin antibody (Dako
Cytomation) (1/50 dilution in 0.5% Tween 20 and BSA
1%) for 1 h at room temperature in the dark. Before
cytofluorimetric analysis, samples were washed with PBS
and stained with propidium iodide 5 mg/ml (MP Biome-
dicals) and RNAse (MP Biomedicals) 1 mg/ml in PBS
overnight at 4°C in the dark.
Statistical analysis
Differences between dose response, apoptosis and sche-
dules of treatments were determined using the Student's
t test for unpaired observations. Statistical analyses were
performed using the Statistical Package for Social Sci-
ence (SPSS, version 17.0) and statistical significance was
defined as p < 0.05. All p values were two-sided.
Results
Cytotoxic activity
Treatment cytotoxicity was assessed at scalar drug con-
centrations and IC50 value was calculated (Figure 2).
The values of IC50 for RS were lower than those for
NRS in all cell lines tested.
Triple negative cell lines
The NRS treatment induced, in MDA-MB-231 cells, a
IC50 mean value of 29 μM compared to 23 μM for RS,
with a decrease of 26% compared to standard treatment,
(p =0.042) (Figure 2). BRC-230 cells were more sensitive
to Zol for both schedules, and more specifically, the
IC50 decrease was 14% greater with RS compared to
NRS (p =0.003). Moreover, a cytocidal effect was
observed with RS, inducing a LC50 of 49 μM and 40 μM
in MDA-MB-231 and BRC-230, respectively.
MCF-7 and SkBr3 cell lines
NRS treatment induced IC50 values of 23.6 μM and
25.2 μM in MCF-7 and SKBr3, respectively, while the RS
schedule resulted in IC50 values of 29.0 μM (MCF-7)
and 26.4 μM (SKBr3) (Figure 2). Neither of the two
treatment schedules induced a cytocidal effect. As the
highest concentration produced the strongest effect in
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all cell lines, this was chosen for all subsequent
experiments.
Effect of zoledronic acid on the mevalonate pathway and
proliferation markers
Triple negative cell lines
Both treatments induced a strong reduction in RAS ex-
pression in MDA-MB-231 and BRC-230 cells. There was
no difference in MAPK levels after treatment in BRC-
230 cell lines, whereas a strong decrease was observed
after both treatments in MDA-MB-231 cells. Further-
more, a strong reduction of (Figure 3) pMAPK was
observed in BRC-230 and, only slightly, in MDA-MB-
231. Although both schedules inhibited the migration
power of both cell lines, the reduction was more evident
in BRC-230 (Figure 4). This result was confirmed by
western blot analysis of RHO, which decreased after
treatment.
We evaluated Ras activity in MDA-MB-231 and
observed a 50% decrease in its activity in both schedules.
Ras expression levels decreased by about tenfold in cells
exposed to RS and by about twofold in NRS-treated cells
compared to control (Figure 5). Expressing this result as
the ratio Ras expression/Ras activity in cells exposed to
RS, we observed a difference between treated and non
treated cells. No difference was found in Rho activity be-
fore or after treatment (data not shown).
MCF-7 and SkBr3 cell lines
In these two cell lines, the decrease in RAS and pMAPK
was lower compared to that observed in triple-negative
cells, and was more evident in SKBr3 cells (Figure 3).
MAPK levels showed no change after treatment in
MCF-7 cell lines, while a slight increase in expression
was observed after treatment with RS in SKBr3. Both
treatment schedules did not modify the migration power
of either cell line. This result was also confirmed by the
absence of modulation of RHO expression by western
blot (Figure 4).
The differences observed in the cytotoxicity data and
in the modulation of the mevalonate pathways cannot be
attributed to a different uptake of Zol of the cell lines. In
fact, no difference was detected in the accumulation of
unprenylated Rap1A, a surrogate marker of Zol uptake
(Figure 5).
Figure 2 Comparison between the two drug schedules, repeated (RS) and non-repeated (NRS). Data represent the mean ± standard
deviation (SD) of three independent experiments. Error bars represent the mean ± SD. A) Dose-effect curves of Zol in breast cancer cell lines.
Standard deviation never exceeded 5%. B) IC50 and LC50 values in the 2 treatment schedules. Asterisks refer to values that differ significantly
(p <0.05) with respect to control values. n.r., not reached.
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Apoptosis
Triple negative cell lines
Zol induced apoptosis in both the triple negative cell
lines used as experimental models (Figure 6). Both
treatment schedules induced a significant percentage of
apoptotic cells compared to the untreated control. How-
ever, MDA-MB-231 showed a higher percentage of apop-
totic cells following RS compared to NRS treatment,
Figure 4 Migration ability after treatment with Zol. A) Wound scratch analysis to test the migration power of BRC-230 cells pre- and
post-treatment. B) Evaluation of Rho expression by western blot analysis.
Figure 3 Effect of Zol on the mevalonate pathway and on proliferation markers. A) Western blot analyses. B) Ras activity evaluated by
western blot. C) Band density quantifications by Quantity one software.
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without reaching statistical significance (44% compared to
30.6%). Conversely, BRC-230, showed a higher percentage
of apoptotic cells after NSR treatment (48%) compared to
RS (40%), without reaching statistical significance. Apop-
tosis was confirmed by western blot by a decrease in the
levels of pro-caspase 3, 8 and 9 in both cell lines, without
detection of the active forms. In MDA-MB-231, the levels
of Bcl2 expression decreased after both treatments,
whereas in BRC-230 the protein was not appreciably
expressed (Figure 6). Furthermore, a decrease of mcl-1
expression was detected in both cell lines.
MCF-7 and SkBr3 cell lines
No apoptosis was observed in MCF-7, even if we
detected the presence of debris, indicating early cell
death. An almost complete disappearance of Bcl2 ex-
pression was also observed in MCF7 cells treated with
RS. In SKBr3, the percentage of apoptotic cells was
higher in treated cells following both treatment sche-
dules compared to untreated control (not significant)
(Figure 6). In addition, a strong reduction of MCL-1 was
observed only in the SKBr3 cell line for both treatments.
However, NRS treatment induced a higher percentage of
Figure 5 Evaluation of Rap1a levels by western blot analysis.
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Figure 6 Apoptotic cells evaluated by TUNEL assay. Data represent the mean ± SD of three independent experiments. Error bars represent
the mean ± SD. *p <0.05, ** p <0.01. A) Western blot data about modulation of apoptotic markers after the two treatment schedules in the
4 breast cancer cell lines. B) Percentage of cells in apoptosis. Data represent the mean ± SD of three independent experiments. *p <0.05, **p <0.01.
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apoptotic cells (31%) in this cell line compared to the RS
treatment (14%).
Cell cycle analysis
Triple negative cell lines
Both treatment schedules induced a significant increase
of the percentage of cells in G0/G1 in all cell lines used
(Figure 7) compared to untreated controls. The percent-
age of cells that accumulated in G0/G1 was 45.5% higher
after RS with respect to control compared to NRS treat-
ment (16.9%) in the BRC-230 cell line. This accumu-
lation was also confirmed by the increase in p21
expression in RS in MDA-MB-231cells, whereas in
BRC-230, the protein was not appreciably expressed.
p27 expression was not evaluable in either of the two
lines.
MCF-7 and SKBr3 cell lines
In SKBr3 cells, RS treatment induced an accumulation
of cells in G0/G1 resulting in an increase of about 9%
compared to untreated cells (p =0.005). Instead, NRS
induced a cell accumulation in the S phase with a 50%
increase in blocked cells compared to controls (p =0.01).
Cell cycle perturbation was confirmed by an increase in
p27 in both cell lines after Zol treatment.
The pulse-chase experiment was performed on MDA-
MB-231 exposed to RS. After 72 hrs and 168 hrs all un-
treated cells were BrdU-positive, indicating that every
cell had entered S phase at least once and that there was
a regular cell proliferation. Conversely, after the same
times treated cells showed a fraction of BrdU-negative
cells, confirming that Zol had arrested a certain percent-
age of cells in G0/1 phase. Of note, very few treated cells
(BrdU-positive or -negative) entered or left S phase after
72 hrs, as also shown by the absence of clearly visible S
and G2/M phases on the propidium iodide fluorescence
axis (Figure 8). Forty-eight hrs after the end of treatment
almost all cells were dead or in late-stage apoptosis and
could thus no longer usable for S phase evaluation (data
not shown).
Figure 7 Effect of Zol on the cell cycle. A) Distribution of cells in the different cell cycle phases pre- and post-treatment. B) All p values
were < 0.01 with the exception of S phase of BRC-230 cells exposed to NRS, G2/M phase of MDA-MB-231 cells exposed to NRS and G2/M of
SkBr3 cells exposed to both treatments. C) Expression of p21 and p27 pre- and post-treatment in the different cell lines.
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Discussion
In the present study, Zol induced cytostatic and cytoci-
dal effects on breast cancer cell lines, in agreement with
results from previous papers [38,39]. To mimic the bone
microenvironment, concentrations of Zol used in our
experiments (12.5, 25, 50 μM) were higher than the
transient circulatory levels detected in patients. However,
the concentrations used were in agreement with previ-
ously reported in vitro and in vivo data [15,40-43].
Moreover, it is well known that the pharmacokinetics
and pharmakodinamic properties of Zol result in a rapid
drug elimination by renal excretion and rapid uptake
and accumulation within bone [44,45]. This accumula-
tion has also been supported by a xenograft study which
showed a high bisphosphonate concentration in bone
compared to plasma [46]. For the reasons described
above, we decided to use a higher concentration com-
pared to that utilized in the clinical setting.
As expected, Zol exerted dose-dependent effects on
cell proliferation in all cell lines following both treat-
ment exposures. However, the repeated treatment
induced a statistically significant modulation of cell pro-
liferation and cytotoxic effect only in triple negative
breast cancer cell lines. These data support results
obtained in a preclinical model of bone metastasis
induced in a triple negative cell line, showing that the
antitumor effect of bisphosphonates increases when the
drug is administered at low dose with a daily or weekly
schedule [21], inducing a reduction of osteolyisis and
growth of tumor in the bone.
Our results also confirm recent findings on the
increased delivery of Zol to cancer cells both in vitro
and in vivo through the use of liposomes or nanoparti-
cles. It is hypothesized that the delivery of Zol by ‘stealth’
nanovectors mimics repeated administrations of Zol,
and this would seem to be confirmed by the increased
in vitro activity of the nanodevices encapsulating Zol
[47-49].
Zol is known to block enzymes of the mevalonate
pathway such as farnesyl pyrophosphate synthase, and/
or geranylgeranyl pyrophosphate synthase [50]. This
block causes a deficiency in isoprenoids which are essen-
tial for the post-translation lipid modification of signal-
ling GTPases such as RHO and RAS [10,51,52]. To our
knowledge, ours is the first Zol study on triple-negative
lines to observe a modulation of RAS and RHO
Figure 8 Pulse-chase experiments on MDA-MB-231. Experiments performed on cells treated with RS. Analysis of control cells at baseline, after
72 h and after 168 h (end of treatment), and of treated cells after 72 h and 168 h.
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pathways; indeed, the decrease in RAS and pMAPK ex-
pression could explain the observed inhibition of cell
proliferation. We also observed a decrease in RAS activ-
ity after treatment.
The wound scratch test showed a decrease of the mi-
gration power of triple-negative treated cells, most prob-
ably due to a decrease in RHO expression. The
induction of the caspase pathway by Zol supports the
hypothesis that apoptosis is linked to these pathways in
triple-negative cell lines. Conversely, in HER2 overes-
pressing (SKBr3) and positive hormone receptor cells
(MCF-7), Zol induced only a cytostatic effect. In fact, a
block (inhibition) of the RAS pathway was observed,
with a reduction of pMAPK expression in SKBr3 cells,
confirming the action of Zol to inhibit the mevalonate
pathway.
There are conflicting literature data on breast cancer
sensitivity to Zol, possibly due to the different HER2 and
hormone receptors’ patterns of breast cancers. A study
reported that MCF-7 and MDA-MB-231 cell lines were
similarly sensitive to bisphosphonates [53]. Conversely,
another study reported that clodronate reduced cell sur-
vival of MDA-MB-231, but not MCF-7 cells [54]. Hu
et al. have characterized genetic alterations and onco-
genic pathway in different breast cancers subtypes, both
in tissue and in cell lines, and found that all mutations
in BRAF, KRAS and HRAS were significantly associated
with the triple negative subtype [55]. We hypothesized
that triple-negative cell lines are more sensitive to Zol
because the mevalonate pathway is blocked and the
KRAS pathway is constitutively active. This hypothesis
fits in with the MDA-MB-231 cell line profile, which
harbors mutated KRAS and BRAF, while BRC-230 did
not present any BRAF, KRAS and HRAS alterations (data
not shown). However, BRC-230, presented a genetic
amplification of EGFR and concomitant overexpression
of the protein as observed in triple-negative breast can-
cers [56]. The hormone receptor (MCF-7) and HER2-
positive (SKBr3) cell lines, not presenting any alterations
in BRAF, KRAS, NRAS, HRAS or EGFR, appear to be less
sensitive to both Zol schedules. A possible explanation
could be the lack of caspase 3 in MCF-7 [41] and the
overexpression of HER2 in SKBr3, which are involved in
overcoming inhibition of the RAS pathway.
Conclusions
Our work confirms the direct antitumor activity of Zol
in human cell lines, as previously reported in in vitro
and mouse models [21,22] and recently observed in
patients in the Azure trial [57]. Furthermore, we high-
lighted an increase in the efficacy of Zol with repeated
doses. In addition, the two triple-negative breast cancer
cell lines were more sensitive to Zol than the other cell
lines. These results indicate that it would be interesting
to carry out further trials on animal models and, after
successful completion, on patients. Finally, we per-
formed an in-depth study of the mechanisms of action
of Zol, observing that the KRAS/BRAF pathways are
probably responsible for the sensitivity of the triple
negative cell line. These data provide a sound rationale
for using biologically targeted drugs for KRAS/BRAF/
EGFR inhibition in combination with Zol. PARP inhibi-
tors are another drug group that could potentially be
used with Zol. Such hypotheses obviously need to be
confirmed but are interesting in view of the limited
treatment options available for patients with triple-
negative breast cancer.
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